行政院衛生署 (2009)。2005-2008年國民營養健康狀況變遷調查結果，
國人血漿血糖異常之狀況。http://nahsit.nhri.org.tw/node/19。取至100年11月10日。
朱俊源、李文賢、許柏超、蘇河名、林宗憲、溫文才、賴文德、許勝雄 (2013)。以心臟科醫師的角度來看糖尿病藥物的使用。內科學誌，24，12-8。何敏夫 (2002)。血液學。合計圖書出版社，台北。
食品衛生消費者資訊網 (2011)。食在安心。研究調查，國民營養調查，2005-2008台灣國民營養健康狀況變遷調查結果。http://consmer.fda.gov.
tw/Pages/List.aspx?nodeID=287。取自100年11月10日。
高美丁 (2008)。膳食療養學二版。華格納企業。台中
喬長誠 (2006)。蝦紅素。元氣齋書出版社，台灣。
詹雯娟 (2006)。維生素C與維生素E之補充對第2型糖尿病患凝血及抗凝血因子活性之影響。靜宜大學食品營養學系研究所碩士論文。潘文涵、吳幸娟、葉志嶸、莊紹源、張新儀、葉乃華、謝耀德 (2009)。台灣人飲食與健康之趨勢：1993-1996 與2005-2008兩次營養健康調查之比較。https://consumer.fda.gov.tw/Files/doc/3.%E5%8F%B0%E7%81%A3%E4
%BA%BA%E9%A3%B2%E9%A3%9F%E8%88%87%E5%81%A5%E5%BA%B7%E4%B9%8B%E8%B6%A8%E5%8B%A2%201993-1996%E8%88%872005-2008%E7%87%9F%E9%A4%8A%E5%81%A5%E5%BA%B7%E8%AA%BF%E6%9F%A5%E4%B9%8B%E6%AF%94%E8%BC%83.pdf。取自版103年01月10日。
潘姵錚 (2010)。蝦紅素對streptozotocin誘發之糖尿病大鼠致血栓危險性之探討。靜宜大學食品營養學系研究所碩士論文。衛生福利部 (2012)。101年度死因統計。http://www.mohw.gov.tw/cht/ DOS/ Statistic.aspx?f_list_no=312&fod_list_no=2747。取自版103年05月21日。
Abuja PM, Albertini R. Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. Clin Chim Acta. 2001;306:1-17.
Adeghate E. Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review. Mol Cell Biochem. 2004;261:187-91.
Ahmad M, Khan MA, Khan AS. Naturally occurring antioxidant vitamin levels in patients with type-II diabetes mellitus. JAMC. 2003;15:54-7.
Ahmed N. Advanced glycation endproducts--role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005;67:3-21.
Ahrens B. Antibodies in metabolic diseases. New Biotechnol. 2011;28:530-7.
American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes care. 2013;36:S67-73
Antoniades C, Tousoulis D, Tentolouris C, Toutouza M, Marinou K, Goumas G, Tsioufis C, Toutouzas P, Stefanadis C. Effects of antioxidant vitamins C and E on endothelial function and thrombosis/fibrinolysis system in smokers. Thromb Haemost. 2003;89:990-5.
Aoi W, Naito Y, Sakuma K, Kuchide M, Tokuda H, Maoka T, Toyokuni S, Oka S, Yasuhara M, Yoshikawa T. Astaxanthin limits exercise-induced skeletal and cardiac muscle damage in mice. Antioxid Redox Signal. 2003;5:139-44.
Aronson D. Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol. 2008;45:1-16.
Arunkumar E, Bhuvaneswari S, Anuradha CV. An intervention study in obese mice with astaxanthin, a marine carotenoid--effects on insulin signaling and pro-inflammatory cytokines. Food Funct. 2012;3:120-6.
Aso Y, Matsumoto S, Fujiwara Y, Tayama K, Inukai T, Takemura Y. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1. Metabolism. 2002;51:471-6.
Aso Y, Wakabayashi S, Yamamoto R, Matsutomo R, Takebayashi K, Inukai T. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. Diabetes Care. 2005;28:2211-6.
Augusti PR, Conterato GM, Somacal S, Sobieski R, Quatrin A, Maurer L, Rocha MP, Denardin IT, Emanuelli T. Astaxanthin reduces oxidative stress, but not aortic damage in atherosclerotic rabbits. J Cardiovasc Pharmacol Ther. 2009;14:314-22.
Babiak J, Rudel LL. Lipoproteins and atherosclerosis. Baillieres Clin Endocrinol Metab. 1987;1:515-50.
Banerjee RN, Sahni AL, Kumar V, Arya M. Antithrombin III deficiency in maturity onset diabetes meliitus and atherosclerosis. Thromb Diath Haemorrh. 1974;31:339-45.
Balleisen L, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost. 1985;54:475-9.
Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA. RAGE biology, atherosclerosis and diabetes. Clin Sci. 2011;121:43-55.
Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM, De Caterina R. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation. 2002;105:816-22.
Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 2004;63:582-92.
Bell JG, McEvoy J, Tocher DR, Sargent JR. Depletion of alpha-tocopherol and astaxanthin in Atlantic salmon (Salmo salar) affects autoxidative defense and fatty acid metabolism. J Nutr. 2000;130:1800-8.
Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004;104:100-6.
Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-7.
Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 2004;279:48487-90.
Blüher M, Fasshauer M, Tönjes A, Kratzsch J, Schön MR, Paschke R. Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes. 2005;113:534-7.
Blum S, Vardi M, Levy NS, Miller-Lotan R, Levy AP. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Atherosclerosis. 2010;211:25-7.
Boneu B, Abbal M, Plante J, Bierme R. Letter: Factor-VIII complex and endothelial damage. Lancet. 1975 ;1:1430.
Brosius FC, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, Takahashi T. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2005;16:27-45.
Brownlee M, Vlassara H, Cerami A. Inhibition of heparin-catalyzed human antithrombin III activity by nonenzymatic glycosylation. Possible role in fibrin deposition in diabetes. Diabetes. 1984;3:532-5.
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615-25.
Budin SB, Top AGM, Mohamud WNW, Bakar M A, Osman K, Eng MYS, Mohamed J. The Effects of Palm Vitamin E Supplementation on Glycemic Control and Lipid Profile in Streptozotocin-Induced Diabetic Rats. Jurnal Sains Kesihatan Malaysia. 2005; 3:1-12.
Budin SB, Othman F, Louis SR, Bakar MA, Das S, Mohamed J. The effects of palm oil tocotrienol-rich fraction supplementation on biochemical parameters, oxidative stress and the vascular wall of streptozotocin-induced diabetic rats. Clinics. 2009;64:235-44.
Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther. 2008;88:1322-35.
Calles-Escandon J, Garcia-Rubi E, Mirza S, Mortensen A. Type 2 diabetes:
one disease, multiple cardiovascular risk factors. Coron Artery Dis. 1999;10:23-30.
Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical
perspective. Endocr Rev. 2001;22:36-52.
Campbell RK. Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies. J Am Pharm Assoc. 2009;49:S3-9.
Carmassi F, Morale M, Puccetti R, De Negri F, Monzani F, Navalesi R, Mariani G. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res. 1992;67:643-54.
Carr ME. Diabetes mellitus:A hypercoagulable state. J Diabetes Complications. 2001;15:44-54.
Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, Anfossi G, Costa G, Trovati M. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab. 2006;91:813-9.
Ceriello A, Dello Russo P, Zuccotti C, Florio A, Nazzaro S, Pietrantuono C, Rosato GB. Decreased antithrombin III activity in diabetes may be due to non-enzymatic glycosylation--a preliminary report. Thromb Haemost. 1983;50:633-4.
Ceriello A, Giugliano D, Quatraro A, Consoli G, Stante A, Dello Russo P, D'Onofrio F. Induced hyperglycemia alters antithrombin III activity but not its plasma concentration in healthy normal subjects. Diabetes. 1987;36:320-3.
Ceriello A, Quatraro A, Dello Russo P, Marchi E, Barbanti M, Milani MR, Giugliano D. Protein C deficiency in insulin-dependent diabetes: a hyperglycemia-related phenomenon. Thromb Haemost. 1990;64:104-7.
Ceriello A, Giugliano D, Quatraro A, Marchi E, Barbanti M, Lefèbvre P. Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans. Diabetologia. 1990;33:163-7.
Ceriello A, Quatraro A, Dello Russo P, Marchi E, Barbanti M, Milani MR, Giugliano D. Protein C deficiency in insulin-dependent diabetes: a hyperglycemia-related phenomenon. Thromb Haemost. 1990;64:104-7.
Ceriello A, Giugliano D, Quatraro A, Donzella C, Dipalo G, Lefebvre PJ. Vitamin E reduction of protein glycosylation in diabetes. New prospect for prevention of diabetic complications? Diabetes Care. 1991;14:68-72.
Ceriello A, Taboga C, Tonutti L et al. Post-meal coagulation activation in diabetes mellitus: the effect of Acarbose. Diabetologia. 1996;39:469-73.
Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev. 2000;16:125-32.
Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia. 2003;46:9-16.
Ceriello A. Diabetic complications: from oxidative stress to inflammatory cardiovascular disorders. Medicographia. 2011;33:29-34.
Chan KC, Mong MC, Yin MC. Antioxidative and anti-inflammatory neuroprotective effects of astaxanthin and canthaxanthin in nerve growth factor differentiated PC12 cells. J Food Sci. 2009;74:225-31.
Chan KC, Pen PJ, Yin MC. Anticoagulatory and antiinflammatory effects of astaxanthin in diabetic rats. J Food Sci. 2012;77:76-80.
Chew BP, Mathison BD, Hayek MG, Massimino S, Reinhart GA, Park JS. Dietary astaxanthin enhances immune response in dogs. Vet Immunol Immunopathol. 2011;140:199-206.
Choy CK, Rodgers JE, Nappi JM, Haines ST. Review of therapeutics: Type 2 diabetes mellitus and heart failure. Pharmacotherapy. 2008;28:170-92.
Chung SS, Ho EC, Lam KS, Chung SK. Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol. 2003;14:233-6.
Collier A, Rumley A, Rumley AG, Paterson JR, Leach JP, Lowe GD, Small M. Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes. 1992;41:909-13.
Conlan MG, Folsom AR, Finch A, Davis CE, Marcucci G, Sorlie P, Wu KK. Antithrombin III: associations with age, race, sex and cardiovascular disease risk factors. Thromb Haemost. 1994;72:551-6.
Connelly JB, Roderick PJ, Cooper JA, Meade TW, Miller GJ. Positive association between self-reported fatty food consumption and factor VII coagulant activity, a risk factor for coronary heart disease, in 4246 middle-aged
men. Thromb Haemost. 1993;70:250-2.
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-7.
Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111:1448-54.
Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-97.
Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res. 2007;55:498-510.
De Lange M, Snieder H, Ariëns RA, Spector TD, Grant PJ. The genetics of haemostasis: a twin study. Lancet. 2001;357:101-5.
De Sousa JC, Soria C, Ayrault-Jarrier M, Pastier D, Bruckert E, Amiral J, Caen, JP. Association between coagulation factors VII and X with triglyceride rich lipoproteins. J Clin Pathol. 1988;41:940-4.
Devaraj S, Jialal I. Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. Free Radic Biol Med. 2000;29:790-2.
Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation. 2003;107:398-404.
Donath MY, Størling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med. 2003;81:455-70.
Dong LY, Jin J, Lu G, Kang XL. Astaxanthin attenuates the apoptosis of retinal ganglion cells in db/db mice by inhibition of oxidative stress. Mar Drugs. 2013; 11:960-74.
D'Orazio N, Gammone MA, Gemello E, De Girolamo M, Cusenza S, Riccioni G. Marine bioactives: pharmacological properties and potential applications against inflammatory diseases. Mar Drugs. 2012;10:812-33.
Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl
Acad Sci. 2000;97:12222-6.
Erba D, Riso P, Criscuoli F, Testolin G. Malondialdehyde production in Jurkat T cells subjected to oxidative stress. Nutrition. 2003;19:545-8.
Esmon CT. The protein C pathway. Chest. 2003;124:26-32.
Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106:2067-72.
Fassett RG, Coombes JS. Astaxanthin: a potential therapeutic agent in cardiovascular disease. Mar Drugs. 2011; 9: 447-65.
Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51:1131-7.
Foster M, Petocz P, Samman S. Inflammation markers predict zinc transporter gene expression in women with type 2 diabetes mellitus. J Nutr Biochem. 2013;24:1655-61.
Frankel DS, Meigs JB, Massaro JM, Wilson PW, O'Donnell CJ, D'Agostino RB, Tofler GH. Von Willebrand Factor, Type 2 Diabetes Mellitus, and Risk of Cardiovascular Disease The Framingham Offspring Study. Circulation. 2008;118, 2533-9.
Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51:1596-600.
Friedman EM, Herd P. Income, education, and inflammation : differential associations in a national probability sample (The MIDUS study). Psychosom Med. 2010;72:290-300.
Fuller JH, Keen H, Jarrett RJ, Omer T, Meade TW, Chakrabarti R, North WR, Stirling Y. Haemostatic variables associated with diabetes and its complications. Br Med J. 1979;2:964-6.
Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114:1752-61.
Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058-70.
Gisinger C, Jeremy J, Speiser P, Mikhailidis D, Dandona P, Schernthaner G. Effect of vitamin E supplementation on platelet thromboxane A2 production in type I diabetic patients. Double-blind crossover trial. Diabetes. 1988;37:1260-4.
Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996;19:257-67.
Goh SY, Cooper ME. Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008;93:1143-52.
Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009;94:3171-82.
Goldstein DE, Peth SB, England JD, Hess RL, Da Costa J. Effects of acute changes in blood glucose on HbA1c. Diabetes. 1980;29:623-8.
Goto S, Kogure K, Abe K, Kimata Y, Kitahama K, Yamashita E, Terada H. Efficient radical trapping at the surface and inside the phospholipid membrane is responsible for highly potent antiperoxidative activity of the carotenoid astaxanthin. Biochim Biophys Acta. 2001;1512:251-8.
Guerin M, Huntley ME, Olaizola M. Haematococcus astaxanthin: Applications for human health and nutrition. Trends Biotechnol. 2003;21:210-6.
Gugliucci A, Menini T. The botanical extracts of Achyrocline satureoides and Ilex paraguariensis prevent methylglyoxal-induced inhibition of plasminogen and antithrombin III. Life Sci. 2002;72:279-92.
Gupta D, Griendling KK, Taylor WR. Oxidative Stress and Cardiovascular Disease in Diabetes Mellitus. Studies on Cardiovascular Disorders. 2010;
263-79.
Haghighat N, Vafa MR, Eghtesadi S, Heidari I, Hoseini AF. The effects of tocotrienol-enriched canola oil on inflammation, nitrosative stress and urinary microalbumin in patients with type-2 diabetes: arandomized double-blind clinical trial. Iranian Journal of Nutrition Sciences & Food Technology. 2013; 8:1-9.
Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008;29:2959-71.
Hasanain B, Mooradian AD. Antioxidant vitamins and their influence in diabetes mellitus. Curr Diab Rep. 2002;2:448-56.
Hengst JM. The role of C-reactive protein in the evaluation and management of infants with suspected sepsis. Adv Neonatal Care. 2003;3:3-13.
Hirano T, Kashiwazaki K, Moritomo Y, Nagano S, Adachi M. Albuminuria is directly associated with increased plasma PAI-1and factor VII levels in NIDDM patients. Diabetes Res Clin Pract. 1997;36:11-8.
Hussein G, Sankawa U, Goto H, Matsumoto K, Watanabe H. Astaxanthin, a carotenoid with potential in human health and nutrition. J Nat Prod. 2006;69:443-9.
Hussein G, Nakagawa T, Goto H, Shimada Y, Matsumoto K, Sankawa U, Watanabe H. Astaxanthin ameliorates features of metabolic syndrome in SHR/NDmcr-cp. Life Sci. 2007;80:522-9.
Iacoviello L, Di Castelnuovo A, De Knijff P, D'Orazio A, Amore C, Arboretti R, Kluft C, Benedetta Donati M. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med. 1998;338:79-85.
Ikeuchi M, Koyama T, Takahashi J, Yazawa K. Effects of astaxanthin in obese mice fed a high-fat diet. Biosci Biotechnol Biochem. 2007;71:893-9.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-96.
Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, Corat MA, Zeier M, Blessing E, Oh J, Gerlitz B, Berg DT, Grinnell BW, Chavakis T, Esmon CT, Weiler H, Bierhaus A, Nawroth PP. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med. 2007;13:1349-58.
Jain SK, Palmer M. The effect of oxygen radicals metabolites and vitamin E on glycosylation of proteins. Free Radic Biol Med. 1997;22:593-6.
Jeong SM, Kang MJ, Choi HN, Kim JH, Kim JI. Quercetin ameliorates hyperglycemia and dyslipidemia and improves antioxidant status in type 2 diabetic db/db mice. Nutr Res Pract. 2012;6:201-7.
Jeppsson JO, Kobold U, Barr J, Finke A, Hoelzel W, Hoshino T, Miedema K, Mosca A, Mauri P, Paroni R, Thienpont L, Umemoto M, Weykamp C. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med. 2002;40:78-89.
Ji C, Rouzer CA, Marnett LJ, Pietenpol JA. Induction of cell cycle arrest by the endogenous product of lipid peroxidation, malondialdehyde. Carcinogenesis. 1998;19:1275-83.
Jia Y, Kim JY, Jun HJ, Kim SJ, Lee JH, Hoang MH, Hwang KY, Um SJ, Chang HI, Lee SJ. The natural carotenoid astaxanthin, a PPAR-α agonist and PPAR-γ antagonist, reduces hepatic lipid accumulation by rewiring the transcriptome in lipid-loaded hepatocytes. Mol Nutr Food Res. 2012;56:878-88.
Junker R, Heinrich J, Schulte H, Loo J van de, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscl Throm Vas. 1997;17:1539-44.
Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784-92.
Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1:15-25.
Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, Kasuga M. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2006;116:1494-505.
Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, Chugh S, Danesh FR. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med. 2008;233:4-11.
Kessler L, Wiesel ML, Attali P, Mossard JM, Cazenave JP, Pinget M. Von Willebrand factor in diabetic angiopathy. Diabetes Metab. 1998;24:327-36.
Khan SK, Malinski T, Mason RP, Kubant R, Jacob RF, Fujioka K, Denstaedt SJ, King TJ, Jackson HL, Hieber AD, Lockwood SF, Goodin TH, Pashkow FJ, Bodary PF. Novel astaxanthin prodrug (CDX-085) attenuates thrombosis in a mouse model. Thromb Res. 2010;126:299-305.
Kim JH, Chang MJ, Choi HD, Youn YK, Kim JT, Oh JM, Shin WG. Protective effects of Haematococcus astaxanthin on oxidative stress in healthy smokers. J Med Food. 2011;14:1469-75.
Kim YJ, Kim YA, Yokozawa T. Protection against Oxidative Stress, Inflammation, and Apoptosis of High-Glucose-Exposed Proximal Tubular
Epithelial Cells by Astaxanthin. J Agric Food Chem. 2009;57:8793-7.
Knöbl P, Schernthaner G, Schnack C, Pietschmann P, Griesmacher A, Prager R, Müller M. Thrombogenic factors are related to urinary albumin excretion rate in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:1045-50.
Kohriyama T, Katayama S, Tanaka E, Yamamura Y, Nakamura S. Coagulation
and fibrinolytic parameters in pateints with various angiopathies—analysis
in cerebral thrombosis, diabetic and vasculitic neuropathies. Rinsho Shinkeigaku. 1993;33:606-11.
Larsen LF, Bladbjerg EM, Jespersen J, Marckmann P. Effects of dietary fat quality and quantity on postprandial activation of blood coagulation factor VII. Arterioscler Thromb Vasc Biol. 1997;17:2904-9.
Lee SJ, Bai SK, Lee KS, Namkoong S, Na HJ, Ha KS, Han JA, Yim SV, Chang K, Kwon YG, Lee SK, Kim YM. Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B
kinase-dependent NF-kappaB activation. Mol Cells. 2003;16:97-105.
Lee WJ, Kim M, Park HS, Kim HS, Jeon MJ, Oh KS, Koh EH, Won JC, Kim MS, Oh GT, Yoon M, Lee KU, Park JY. AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARalpha and PGC-1. Biochem Biophys Res Commun. 2006;340:291-5.
Lemkes BA, Hermanides J, DeVries JH, Holleman F, Meijers JCM, Hoekstra JBL. Hyperglycemia: a prothrombotic factor? J Thromb Haemost. 2010;8:1663-9.
Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res. 1997;34:255-65.
Lunghi B, Iacoviello L, Gemmati D, Dilasio MG, Castoldi E, Pinotti M, Castaman G, Redaelli R, Mariani G, Marchetti G, Bernardi F. Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma. Thromb Haemost. 1996;75:45-8.
Lykkesfeldt J. Malondialdehyde as biomarker of oxidative damage to lipids caused by smoking. Clin Chim Acta. 2007;380:50-8.
Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y. PPAR gamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094-9.
Maleki SJ, Chung SY, Champagne ET, Raufman JP. The effects of roasting on the allergenic properties of peanut proteins. J Allergy Clin Immunol. 2000;106:763-8.
Makin AJ, Blann AD, Chung NA, Silverman SH, Lip GY. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor. Eur Heart J. 2004;25:371-6.
Mannucci PM. von Willebrand Factor A Marker of Endothelial Damage? Arterioscler Thromb Vasc Biol. 1998;18:1359-62.
Marcman P, Sandström B, Jespersen J. Effects of total fat content and fatty acid composition in diet on factor VII coagulant activity and blood lipids. Atherosclerosis. 1990;80:227-33.
Marin DP, Bolin AP, Macedo Rde C, Sampaio SC, Otton R. ROS production in neutrophils from alloxan-induced diabetic rats treated in vivo with astaxanthin. Int Immunopharmacol. 2011;11:103-9.
Marnett LJ. Lipid peroxidation—DNA damage by malondialdehyde. Mutat Res. 1999;424:83-95.
Matés JM, Pérez-Gómez C, Núñez de Castro I. Antioxidant enzymes and human diseases. Clin Biochem. 1999;32:595-603.
McVicar CM, Hamilton R, Colhoun LM, Gardiner TA, Brines M, Cerami A, Stitt AW. Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy. Diabetes. 2011;60:2995-3005.
Michailidou Z, Turban S, Miller E, Zou X, Schrader J, Ratcliffe PJ, Hadoke PW, Walker BR, Iredale JP, Morton NM, Seckl JR. Increased angiogenesis protects against adipose hypoxia and fibrosis in metabolic disease-resistant 11β-hydroxysteroid dehydrogenase type 1 (HSD1)-deficient mice. J Biol Chem. 2012;287:4188-97.
Miki W. Biological functions and activities of animal carotenoids. Pure Appl Chem. 1991;63:141-6.
Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2000;11:212-7.
Monnier L, Follea G, Mirouze J. Antithrombin III deficiency in diabetes mellitus: influence on vascular degenerative complications. Horm Metab Res. 1978;10:470-3.
Mozafari H, Rahimi Z, Heidarpour A, Fallahi M, Muniz A. The prevalence of factor V Leiden, prothrombin G20210A and methylenetetrahydrofolate reductase C677T among G6PD defi-cient individuals from Western Iran. Mol Biol Rep. 2009;36:2361-4.
Naito Y, Uchiyama K, Aoi W, Hasegawa G, Nakamura N, Yoshida N, Maoka T, Takahashi J, Yoshikawa T. Prevention of diabetic nephropathy by treatment with astaxanthin in diabetic db/db mice. Biofactors. 2004;20:49-59.
Nakao R, Nelson OL, Park JS, Mathison BD, Thompson PA, Chew BP. Effect of astaxanthin supplementation on inflammation and cardiac function in BALB/c mice. Anticancer Res. 2010;30:2721-5.
Neelima S, Kafle D, Singh SK, Nivedita S, Singh AK, Vishal B. Type-2 diabetic nephropathy: a proinflammatory cytokine associated disease due to hyperglycemia induced oxidative stress. JARBS. 2012;4:137-40.
Neve BP, Fruchart JC, Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol. 2000;60:1245-50.
Noberasco G, Odetti P, Boeri D, Maiello M, Adezati L. Malondialdehyde (MDA) level in diabetic subjects. Relationship with blood glucose and glycosylated hemoglobin. Biomed Pharmacother. 1991;45:193-6.
Ohgami K, Shiratori K, Kotake S, Nishida T, Mizuki N, Yazawa K, Ohno S. Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Invest Ophthalmol Vis Sci. 2003;44:2694-701.
Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-17.
Onge ELS, Motycka CA, Miller SA. A review of cardiovascular risks associated with medications used to treat type-2 diabetes mellitus. P and T. 2009;34:368-78.
Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, Federspil G, Sechi LA, Vettor R. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol. 2005;152:113-8.
Pandolfi A, Iacoviello L, Capani F, Vitacolonna E, Donati MB, Consoli A. Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture. Diabetologia. 1996;39:1425-31.
Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6. Diabetes Res Clin Pract. 2005;69:29-35.
Park JS, Chyun JH, Kim YK, Line LL, Chew BP. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans.
Nutr Metab. 2010;7:18-27.
Pasaoglu H, Sancak B, Bukan N. Lipid peroxidation and resistance to oxidation in patients with type 2 diabetes mellitus. Tohoku J Exp Med. 2004;203:211-8.
Pashkow FJ, Watumull DG, Campbell CL. Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am J Cardiol. 2008;101:58-68.
Pineda Torra I, Gervois P, Staels B. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol. 1999;10:151-9.
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-34.
Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-703.
Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987;2:1057-8.
Rahbar S. The discovery of glycated hemoglobin: a major event in the study of nonenzymatic chemistry in biological systems. Ann N Y Acad Sci. 2005;1043:9-19.
Ramasamy R, Yan SF, Schmidt AM. The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul Pharmacol. 2012;57:160-7.
Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010; 49:1603–16.
Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci. 2009;84:705-12.
Robinson E, Grieve DJ. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacol Ther. 2009;122:246-63.
Rosenberg R, Damus P. The purification and mechanism of action of
human antithrombin-heparin cofactor. J Biol Chem. 1973;248:6490-505.
Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504-8.
Sacco RL. Risk factors and outcomes for ischemic stroke. Neurology. 1995;45:10-4.
Sadler JE. Minireview: von Willebrand Factor. J Biol Chem. 1991;266: 22777-80.
Sadat Mojani M, Rahmat A, Rainasamy R, Akhavan Hejazi SM. Palm tocotrienols and α- tocopherol attenuate inflammatory biomarkers in streptozotocin-induced diabetic rats. Curr Top Nutraceut R. 2012;10:117-22.
Schafer AI. The hypercoagulable states. Ann Intern Med. 1985;102:814-28.
Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci. 2005;109:143-59.
Segers K, Dahlback B, Nicolaes GA. Coagulation factor V and thrombophilia: background and mechanisms. Thromb Haemost. 2007;98:530-42.
Seghrouchni I, Drai J, Bannier E, Riviere J, Calmard P, Garcia I, Orgiazzi J, Revol A. Oxidative stress parameters in type I, type II and insulin-treated type 2 diabetes mellitus; insulin treatment efficiency. Clin Chim Acta. 2002;321:89-96.
Seligman BG, Biolo A, Polanczyk CA, Gross JL, Clausell N. Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2000;23:1395-400.
Sen CK, Khanna S, Roy S. Tocotrienols: Vitamin E beyond tocopherols. Life Sci. 2006;78:2088-98.
Serbinova E, Kagan V, Han D, Packer L. Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free Radic Biol Med. 1991;10:263-75.
Sharma A, Kharb S, Chugh SN, Kakkar R, Singh GP. Effect of glycemic control and vitamin E supplementation on total glutathione content in non-insulin-dependent diabetes mellitus. Ann Nutr Metab. 2000;44:11-3.
Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y.
Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 1996;2:800-3.
Siddiqui S, Ahsan H, Khan MR, Siddiqui WA. Protective effects of tocotrienols against lipid-induced nephropathy in experimental type-2 diabetic rats by modulation in TGF-β expression. Toxicol Appl Pharmacol. 2013;273:314-24.
Slatter DA, Bolton CH, Bailey AJ. The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia. 2000;43:550-7.
Song F, Jia W, Yao Y, Hu Y, Lei L, Lin J, Sun X, Liu L. Oxidative stress, antioxidant status and DNA damage in patients with impaired glucose regulation and newly diagnosed Type 2 diabetes. Clin Sci. 2007;112:599-606.
Sowers JR, Tuck ML, Sowers DK. Plasma antithrombin III and thrombin generation time: correlation with hemoglobin A1 and fasting serum glucose in young diabetic women. Diabetes Care. 1980;3:655-8.
Spranger J, Kroke A, Möhlig M, Hoffman K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC) -Potsdam Study. Diabetes. 2003;52:812-7.
Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hörmann A, Holle R. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia. 1996;39:1540-5.
Stegenga ME, van der Crabben SN, Levi M, de Vos AF, Tanck MW, Sauerwein HP, van der Poll T. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes. 2006;55:1807-12.
Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes. 2002;51:1157-65.
Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 1992;340:319-23.
Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature. 2001;409:307-12.
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12.
Sun Z, Liu J, Zeng X, Huangfu J, Jiang Y, Wang M, Chen F. Protective actions of microalgae against endogenous and exogenous advanced glycation endproducts (AGEs) in human retinal pigment epithelial cells. Food Funct. 2011;2:251-8.
Sun Z, Liu J, Zeng X, Huangfu J, Jiang Y, Wang M, Chen F. Astaxanthin is responsible for antiglycoxidative properties of microalga Chlorella zofingiensis. Food chemistry. 2011;126:1629-35.
Suzuki Y, Ohgami K, Shiratori K, Jin XH, Ilieva I, Koyama Y, Yazawa K, Yoshida K, Kase S, Ohno S. Suppressive effects of astaxanthin against rat endotoxin-induced uveitis by inhibiting the NF-kappaB signaling pathway. Exp Eye Res. 2006;82:275-81.
Swaroop JJ, Rajarajeswari D, Naidu JN. Association of TNF-α with insulin resistance in type 2 diabetes mellitus. Indian J Med Res. 2012;135:127-30.
Tang WH, Kravtsov GM, Sauert M, Tong XY, Hou XY, Wong TM, Chung SK, Man Chung SS. Polyol pathway impairs the function of SERCA and RyR in ischemic-reperfused rat hearts by increasing oxidative modifications of these proteins. J Mol Cell Cardiol. 2010;49:58-69.
Theriault A, Chao JT, Wang Q, Gapor A, Adeli K. Tocotrienol: a review of its therapeutic potential. Clin Biochem. 1999;32:309-19.
Tomura S, Nakamura Y, Doi M, Ando R, Ida T, Chida Y, Ootsuka S, Shinoda T, Yanagi H, Tsuchiya S, Marumo F. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis. 1996;27:848-54.
Tousoulis D, Antoniades C, Tountas C, Bosinakou E, Kotsopoulou M, Toutouzas P, Stefanadis C. Vitamin C affects thrombosis/ fibrinolysis system
and reactive hyperemia in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2003;26:2749-53.
Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more. Free Radic Biol Med. 2007;43:4-15.
Uchiyama A, Okada Y. Clinical efficacy of astaxanthin-containing haematococcus pluvialis extract for the voluntees at risk of metabolic syndrome. J Clin Biochem Nutr. 2008, 43,38-43.
Uchiyama K, Naito Y, Hasegawa G, Nakamura N, Takahashi J, Yoshikawa T. Astaxanthin protects beta-cells against glucose toxicity in diabetic db/db mice. Redox Rep. 2002;7:290-3.
Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC,
Collen D. Correlation between blood fibrinolytic activity, plasminogen
activator inhibitor level, plasma insulin level, and relative body weight
in normal and obese subjects. Metabolism. 1986;35:250-3.
Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science. 1996;274:787-9.
Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453-7.
Vega-López S, Devaraj S, Jialal I. Oxidative stress and antioxidant supplementation in the management of diabetic cardiovascular disease. J Investig Med. 2004;52:24-32.
Vinik AI. Diabetic neuropathies. Controversies in Treating Diabetes. 2008;135-56.
Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006;4:1186-93.
Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res. 2001;9:414-7.
Vukovich TC, Schernthaner G. Decreased protein C levels in patients with insulin-dependent type I diabetes mellitus. Diabetes. 1986;35:617-9.
Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115:1111-9.
Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J. 1987;245:243-50.
Wu JH, Ward NC, Indrawan AP, Almeida CA, Hodgson JM, Proudfoot1 JM, Puddey IB, Croft KD. Effects of α-Tocopherol and Mixed Tocopherol Supplementation on Markers of Oxidative Stress and Inflammation in Type 2 Diabetes. Clin Chen. 2007;53:511-9.
Wu SJ, Liu PL, Ng LT. Tocotrienol-rich fraction of palm oil exhibits anti-inflammatory property by suppressing the expression of inflammatory mediators in human monocytic cells. Mol Nutr Food Res. 2008;52:921-9.
Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821-30.
Yam ML, Abdul Hafid SR, Cheng HM, Nesaretnam K. Tocotrienols suppress proinflammatory markers and cyclooxygenase-2 expression in RAW264.7 macrophages. Lipids. 2009;44:787-97.
Yamada T, Sato A, Nishimori T, Mitsuhashi T, Terao A, Sagai H, Komatsu M, Aizawa T, Hashizume K. Importance of hypercoagulability over hyperglycemia for vascular complication in type 2 diabetes. Diabetes Res Clin Pract. 2000;49:23-31.
Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941-6.
Yang Y, Seo JM, Nguyen A, Pham TX, Park HJ, Park Y, Kim B, Bruno RS, Lee J. Astaxanthin-rich extract from the green alga Haematococcus pluvialis lowers plasma lipid concentrations and enhances antioxidant defense in apolipoprotein E knockout mice. J Nutr. 2011;141:1611-7.
Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes. 2010;59:249-55.
Yasui Y, Hosokawa M, Mikami N, Miyashita K, Tanaka T. Dietary astaxanthin inhibits colitis and colitis-associated colon carcinogenesis in mice via modulation of the inflammatory cytokines. Chem Biol Interact. 2011;193:79-87.
Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, Haffner S, Hamman RF, Ikram MK, Kayama T, Klein BE, Klein R, Krishnaiah S, Mayurasakorn K, O'Hare JP, Orchard TJ, Porta M, Rema M, Roy MS, Sharma T, Shaw J, Taylor H, Tielsch JM, Varma R, Wang JJ, Wang N, West S, Xu L, Yasuda M, Zhang X, Mitchell P, Wong TY. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-64.
Yildiz D, Zeynep A, Hasan I, Tulay A. Susceptibility of glutathione and glutathionerelated antioxidant activity to hydrogen peroxide in patients with type 2 diabetes: effect of glycemic control. Clin Biochem. 2002;35:297-301.
Yoshida H, Yanai H, Ito K, Tomono Y, Koikeda T, Tsukahara H, Tada N. Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia. Atherosclerosis. 2010;209:520-3.
Yuan JP, Peng J, Yin K, Wang JH. Potential health‐promoting effects of astaxanthin: A high‐value carotenoid mostly from microalgae. Mol Nutr Food Res. 2011;55:150-65.
Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148:209-14.
Zhang X, Zhao WE, Hu L, Zhao L, Huang J. Carotenoids inhibit proliferation and regulate expression of peroxisome proliferators-activated receptor gamma (PPARγ) in K562 cancer cells. Arch Biochem Biophys. 2011;512:96-106.
Ziegler D. Treatment of diabetic neuropathy and neuropathic pain. Diabetes care. 2008;31:255-61.